ARTICLE | Product Development
Long COVID therapies are starting to populate a sparse pipeline
Candidate treatments are split between therapies addressing symptoms versus hypothesized drivers
March 13, 2021 2:52 AM UTC
As Long COVID research ramps up, the first set of therapeutic candidates are either geared toward organ-centered pathology shared with other diseases, or viral and immune mechanisms that could be unifying drivers of the syndrome’s wide-ranging symptoms.
One year into the pandemic, it’s estimated that about 10% of patients who recover from SARS-CoV-2 infection are left with a grab bag of long-lasting symptoms, many of them devastatingly incapacitating...